These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 32988879)

  • 21. E-cadherin expression in molecular types of breast carcinoma.
    Ionescu Popescu C; Giuşcă SE; Liliac L; Avadanei R; Ceauşu R; Cîmpean AM; Balan R; Amălinei C; Ciobanu Apostol D; Căruntu ID
    Rom J Morphol Embryol; 2013; 54(2):267-73. PubMed ID: 23771069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumour-associated endothelial-FAK correlated with molecular sub-type and prognostic factors in invasive breast cancer.
    Alexopoulou AN; Ho-Yen CM; Papalazarou V; Elia G; Jones JL; Hodivala-Dilke K
    BMC Cancer; 2014 Apr; 14():237. PubMed ID: 24693876
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
    Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
    Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
    Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
    J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface.
    Nelson ER; Li S; Kennedy M; Payne S; Kilibarda K; Groth J; Bowie M; Parilla-Castellar E; de Ridder G; Marcom PK; Lyes M; Peterson BL; Cook M; Pizzo SV; McDonnell DP; Bachelder RE
    Oncotarget; 2016 Dec; 7(51):84030-84042. PubMed ID: 27768598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HER2 expression is a strong independent predictor of nodal metastasis in breast cancer.
    Ahmed AR
    J Egypt Natl Canc Inst; 2016 Dec; 28(4):219-227. PubMed ID: 27756653
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metastatic breast carcinoma in pleural fluid: Correlation of receptor and HER2 status with the primary carcinoma-a pilot study.
    Francis IM; Alath P; George SS; Jaragh M; Al Jassar A; Kapila K
    Diagn Cytopathol; 2016 Dec; 44(12):980-986. PubMed ID: 27666130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
    Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
    J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stathmin1 expression is associated with aggressive phenotypes and cancer stem cell marker expression in breast cancer patients.
    Obayashi S; Horiguchi J; Higuchi T; Katayama A; Handa T; Altan B; Bai T; Bao P; Bao H; Yokobori T; Nishiyama M; Oyama T; Kuwano H
    Int J Oncol; 2017 Sep; 51(3):781-790. PubMed ID: 28766688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intraocular Metastases Secondary to Breast Carcinoma Correlates With Upregulation of Estrogen and Progesterone Receptor Expression in the Primary Tumor.
    Parrozzani R; Frizziero L; Testi I; Miglionico G; Perrini P; Pulze S; Pilotto E; Midena E
    Invest Ophthalmol Vis Sci; 2016 Aug; 57(10):3944-8. PubMed ID: 27479811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of p16 and pRB in invasive breast cancer.
    Shin E; Jung WH; Koo JS
    Int J Clin Exp Pathol; 2015; 8(7):8209-17. PubMed ID: 26339389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of a metabolic and canonical biomarker signature in Mexican HR+/HER2-, triple positive and triple-negative breast cancer patients.
    Pacheco-Velázquez SC; Gallardo-Pérez JC; Aguilar-Ponce JL; Villarreal P; Ruiz-Godoy L; Pérez-Sánchez M; Marín-Hernández A; Ruiz-García E; Meneses-García A; Moreno-Sánchez R; Rodríguez-Enríquez S
    Int J Oncol; 2014 Dec; 45(6):2549-59. PubMed ID: 25270118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of aldehyde dehydrogenase 1 (ALDH1) in invasive breast carcinomas.
    Demir H; Dulgar O; Gulle BT; Turna H; Ilvan S
    Bosn J Basic Med Sci; 2018 Nov; 18(4):313-319. PubMed ID: 29924962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.
    Pizzuti L; Krasniqi E; Barchiesi G; Della Giulia M; Izzo F; Sanguineti G; Marchetti P; Mazzotta M; Giusti R; Botticelli A; Gamucci T; Natoli C; Grassadonia A; Tinari N; Iezzi L; Tomao S; Tomao F; Tonini G; Santini D; Astone A; Michelotti A; De Angelis C; Mentuccia L; Vaccaro A; Magnolfi E; Gelibter A; Magri V; Cortesi E; D'Onofrio L; Cassano A; Rossi E; Cazzaniga M; Moscetti L; Omarini C; Piacentini F; Fabbri MA; Scinto AF; Corsi D; Carbognin L; Bria E; La Verde N; Samaritani R; Garufi C; Barni S; Mirabelli R; Sarmiento R; Veltri EM; D'Auria G; Paris I; Giotta F; Lorusso V; Cardillo F; Landucci E; Mauri M; Ficorella C; Roselli M; Adamo V; Ricciardi GRR; Russo A; Berardi R; Pistelli M; Fiorio E; Cannita K; Sini V; D'Ostilio N; Foglietta J; Greco F; Zamagni C; Garrone O; Di Cocco B; Baldini E; Livi L; Desideri I; Meattini I; Sarobba G; Del Medico P; De Tursi M; Generali D; De Maria R; Risi E; Ciliberto G; Sperduti I; Villa A; Barba M; Di Leo A; Vici P
    Int J Cancer; 2020 Apr; 146(7):1917-1929. PubMed ID: 31330065
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histological Features and Tissue Microarray Taxonomy of Nigerian Breast Cancer Reveal Predominance of the High-Grade Triple-Negative Phenotype.
    Titloye NA; Foster A; Omoniyi-Esan GO; Komolafe AO; Daramola AO; Adeoye OA; Adisa AO; Manoharan A; Pathak D; D'Cruz MN; Alizadeh Y; Lewis PD; Shaaban AM
    Pathobiology; 2016; 83(1):24-32. PubMed ID: 26730581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Triple negative breast cancer in people of North East India: critical insights gained at a regional cancer centre.
    Sharma M; Sharma JD; Sarma A; Ahmed S; Kataki AC; Saxena R; Sharma D
    Asian Pac J Cancer Prev; 2014; 15(11):4507-11. PubMed ID: 24969877
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa.
    Hadgu E; Seifu D; Tigneh W; Bokretsion Y; Bekele A; Abebe M; Sollie T; Merajver SD; Karlsson C; Karlsson MG
    BMC Womens Health; 2018 Feb; 18(1):40. PubMed ID: 29444670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression and significance of Twist, estrogen receptor, and E-cadherin in human breast cancer cells and tissues.
    Tan R; Wang L; Song J; Li J; He T
    J Cancer Res Ther; 2017; 13(4):707-714. PubMed ID: 28901319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation between p53 and epidermal growth factor receptor expression in breast cancer classification.
    Wang XZ; Liu Q; Sun JJ; Zuo WS; Hu DW; Ma SG; Mu DB; Yu ZY
    Genet Mol Res; 2015 Apr; 14(2):4282-90. PubMed ID: 25966200
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
    Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
    Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.